Bio-Rad Laboratories Inc. Class A (BIO)
NYSE: BIOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
BIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.84B
- P/E (TTM)
- 46.63
- Forward P/E
- 37.10
- EPS (TTM)
- $7.89
- Dividend yield
- None
- 52-week range
- 236.73 – 396.23
- Day range
- 364.07 – 374.48
- Volume / Avg
- 251.90K / 277.32K
- Beta
- —
- Shares outstanding
- 21.68M
- Next earnings
- Nov 4, 2026
52-week range
BIO stock today
Shares of Bio-Rad Laboratories (BIO) finished lower on Oct 7 at $367.92, a drop of 0.25% or $0.91 per share, versus the S&P 500's 0.22% decline. At this level, BIO sits near the top of its 52-week range of $236.73 to $396.23: 7.1% below the high, set on Aug 27, 2026 and 55.4% above the low. BIO is up 21.4% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 24.1%.
Bio-Rad Laboratories trades at 46.6x its trailing twelve-month earnings per share of $7.89. Its forward P/E of 37.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Bio-Rad Laboratories's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Bio-Rad Laboratories
Company profileBio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Mr. Norman D. Schwartz
- Headquarters
- Hercules, CA
- Employees
- 7,450
- IPO year
- 1980
- Website
- bio-rad.com
Financial highlights
Full financialsIn fiscal 2025, Bio-Rad Laboratories generated $2.58 billion in revenue, up 0.7% from fiscal 2024. Net income was $759.9 million, for a net margin of 29.4% versus a median of -23.9% in the prior 5 years. Gross margin was 51.9% (down from 53.7%) and operating margin 1.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B |
| Growth | +0.65% | -3.92% | -4.67% | -4.12% | +14.81% |
| Net income | $759.90M | $-1.84B | $-637.30M | $-3.63B | $4.25B |
| EPS (diluted) | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 |
Analyst forecast
ForecastConsensus (3 analysts)
hold
Avg. price target
$328.33-10.76%
- Strong buy 1
- Buy 0
- Hold 1
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $2.61
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $13.85 vs —
BIO news
All BIO newsBio-Rad Laboratories peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TXG10x Genomics Inc. Class A | 76.10 | -5.65% | $9.92B | vs BIO |
| AVTRAvantor Inc. | 15.35 | -0.52% | $10.38B | vs BIO |
| BRKRBruker Corporation | 59.72 | -1.29% | $9.10B | vs BIO |
| RVTYRevvity Inc. | 153.60 | +0.20% | $17.14B | vs BIO |
| ALMRAlamar Biosciences Inc. | 27.77 | -13.92% | $1.93B | vs BIO |
| PACBPacific Biosciences of California Inc. | 2.72 | +0.74% | $845.46M | vs BIO |
| CTKBCytek Biosciences Inc. | 5.34 | -0.74% | $694.11M | vs BIO |
| EYPTEyePoint Inc. | 3.32 | +4.73% | $278.35M | vs BIO |
Indexes, lists and sector
Bio-Rad Laboratories stock FAQ
What is Bio-Rad Laboratories's stock price today?
BIO last traded at $367.92 as of Oct 7, 4:00 PM EDT, down 0.25% on the day. Prices are delayed at least 15 minutes.
Does Bio-Rad Laboratories pay a dividend?
No. Bio-Rad Laboratories does not currently pay a regular cash dividend.
When is Bio-Rad Laboratories's next earnings date?
Bio-Rad Laboratories is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $2.61.
What is BIO's P/E ratio?
BIO trades at a trailing P/E ratio of 46.63 and a forward P/E of 37.10.
Who is Bio-Rad Laboratories's CEO?
Mr. Norman D. Schwartz is the chief executive officer of Bio-Rad Laboratories Inc. Class A, which has about 7,450 employees.
Has BIO ever split its stock?
Yes. The most recent BIO stock split was a 2-for-1 split on Mar 8, 2002, one of 5 splits on record.
What is the BIO 52-week high?
The 52-week high for BIO is $396.23 and the 52-week low is $236.73. The stock is currently 7.1% below its high.